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Major problem for diabetic patients represents damage of blood vessels and the oxidative stress of the brain cells due to increased
concentration of free radicals and poor nutrition of brain cells. Gliclazide has antioxidative properties and poor blood brain barrier
(BBB) penetration. Bile acids are known for their hypoglycemic effect and as promoters of drug penetration across biological
membranes. Accordingly, the aim of this study is to investigate whether the bile acid (deoxycholic acid) can change the permeation
of gliclazide, through the blood brain barrier of a ratmodel type-1 diabetes. Twenty-fourmaleWistar ratswere randomly allocated to
four groups, of which, two were given alloxan intraperitoneally (100mg/kg) to induce diabetes. One diabetic group and one healthy
group were given a bolus gliclazide intra-arterially (20mg/kg), while the other two groups apart from gliclazide got deoxycholic
acid (4mg/kg) subcutaneously. Blood samples were collected 30, 60, 150, and 240 seconds after dose, brain tissues were immediately
excised and blood glucose and gliclazide concentrations were measured. Penetration of gliclazide in groups without deoxycholic
acid pretreatment was increased in diabetic animals compared to healthy animals. Also in both, the healthy and diabetic animals,
deoxycholic acid increased the permeation of gliclazide through that in BBB.
1. Introduction
Blood brain barrier (BBB) is selective barrier that eclipsed the
brain and isolates it from the circulating blood. It is com-
posed of the capillary basement membrane (BM), astrocyte
end feet ensheathing the vessels, and pericytes embedded
within the BM [1]. It represents a major barrier for drug
permeation especially those which are highly hydrophilic
and have molecular mass bigger than 400Da. In addition,
efflux protein transporters at the luminal membrane of
the endothelial cells limit the penetration of hydrophobic
molecules. Diabetes mellitus (DM) can lead to disruption in
BBB. A small opening in BBB can have significant impact
on BBB function and structure [2]. Some changes in BBB
occur very fast after animal being in hyperglycemic state.
Previous investigations have shown 30% decrease in brain
glucose uptake in only two days after induction of DM
[3]. Thus it is viable that changes occur also on some
other transport systems but those connected with glucose
transport. Damages of central nervous system (CNS) in DM
occur due to increased concentration of the free radicals and
poor nutrition of the brain cells. Thus, in recent years CNS
becomes a target in the treatment of DM [4, 5].
Gliclazide is a second-generation sulfonylurea, and it
is used in type 2 DM to stimulate insulin production [6].
Sulphonylurea compounds bind to sulphonylurea subunit
(SUR) of ATP sensitive K+ channel (KATP) in pancreas,
which leads to their closure and release of insulin. Gli-
clazide has selective affinity for binding to SUR1 receptors
located mostly in pancreas. Gliclazide is antidiabetic drug
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with antioxidative properties that are independent of any
effect on glucose level [7–9]. Also gliclazide has favorable
hemobiological properties and other extrapancreatic effects
which make gliclazide potentially useful in type 1 DM as
well [10–12]. Because of its scavenging effect and low affinity
for binding to SUR receptors in brain gliclazide is a good
candidate for the investigation as a protector of brain cells in
diabetes. Gliclazide is hydrophobic weak acid that shows low
transfer into the brain tissue [13, 14].
Bile acids are amphiphilic steroids which have been
extensively studied as permeability enhancers of various bio-
logical membranes. Bile salts induce reversible BBB opening
[15]. Part of the effect is hypothesized to be mediated by tight
junction (TJ) modulation [16], cell lysis [17, 18] or incorpora-
tion of bile salts into the lipid bilayer [17]. Detergent activity
and hydrophobicity are properties of bile salts relevant to the
ability to enhance permeability. Deoxycholic acid is natural
bile acid that has good permeator capabilities, and it is widely
investigated in the field of nanotechnology.
The aim of this study was to investigate the efficacy of
sodium salt of deoxycholic acid (DA) as a BBB permeator of
lipophilic molecule gliclazide in healthy and diabetic rats by
in vivo study of gliclazide uptake into the brain tissue after
intra-arterial application of gliclazide by retrograde bolus
injection into the right a. axillaris.
2. Material and Methods
2.1. Animal Treatment
2.1.1. Animals. Male Wistar rats (aged 2-3 months, weight
200–300 g) were housed under 12 h : 12 h light-dark condi-
tions in an experimental animal facility and have food and
water ad libitum. All experiments conducted on animals were
approved by the Animal Ethic Committee of theUniversity of
Novi Sad.
2.1.2. Induction of Diabetes. Diabetes was induced in rats
by the intraperitoneal injection of alloxane (100mg/kg body
weight once a day), for two days, as previously described
[19, 20]. If hyperglycemia in animals persisted for four days
after the second dose of alloxan, animals were included in the
experiment. Blood glucose levels were determined from the
tail vein blood using a glucometer-strip system (Accucheck
Active, Roche). Ratswere considered diabetic if blood glucose
concentrations were >20mmol/L [21].
2.1.3. Experimental Protocol. All groups received microsus-
pension (particle size < 0.5 𝜇m) of gliclazide (20mg/kg)
to the right a. axillaris. DA solution (4mg/kg) was given
subcutaneously 30 minutes before gliclazide dose. Before
preparing blood vessels, the animals were anesthetized with
urethane (1 g/kg) intraperitoneally. Animals were divided
into 4 groups: (1) healthy animals given gliclazide (control),
(2) healthy animals given gliclazide and DA, (3) diabetic
animals given gliclazide, and (4) diabetic animals given
gliclazide and DA (6 rats in each group).
2.2. Sample Preparation and Analyses
2.2.1. Serum Samples Preparation. Blood samples were taken
from the left v. jugularis 30, 60, 150, and 240 seconds after
intra-arterial injection of gliclazide and theywere centrifuged
for 5 minutes (10000 rpm/min). Serums were stored at −20∘C
until analysed. Acetonitrile was added to serum (in a 2 : 1
ratio) vortexed (30 seconds), and centrifuged for 5 minutes
(10000 rpm/min), and then the supernatant (10 𝜇L) was
injected into the HPLC system.
2.2.2. Brain Samples Preparation. The animals were decapi-
tated 240 seconds after gliclazide injection.The cranial bones
were resected and the brain tissue was divided into: the
left and the right cerebral hemisphere (LCH and RCH),
brain stem (BS), and cerebellum (C). After being weighed
brain parts were stored at −20∘C until analysed. Brain parts
were homogenized in a 4-fold volume of distilled water.
Chloroform was added to brain samples in a 4 : 1 ratio and
after vortexing for 30 seconds and centrifuging for 10minutes
on 3500 rpm/min, 1.4mL of the lower layer was transferred
into tubes, evaporated at 70∘C, and before injection onHPLC
system reconstituted with 100 𝜇L of methanol.
2.2.3. HPLC Determination of Gliclazide. Gliclazide concen-
trations in serum and brain samples weremeasured byHPLC
system using the modified method of Mikov et al. [21].
HPLC system (Dionex) consisted of Agilent column (5 𝜇m,
100mm × 2.1mm, 120A∘) with guard column (Agilent; 5𝜇m,
20mm × 2.1mm). The mobile phase consisted of acetonitrile
49% and water 51%, pH 2.7 at flow rate 0.4mL/min. The
retention time for gliclazide was 2.8 minutes. UV detection
was set at 229 nm. Analyses were done at room temperature
(25∘C). The limit of detection (LOD) for brain samples
was 0.02𝜇g/mL and limit of quantification (LOQ) was
0.22𝜇g/mL with recovery of 87.64 ± 3.63 and for serum
samples LOD was 0.2𝜇g/mL and LOQ was 0.5 𝜇g/mL with
recovery of 86.13 ± 3.16%.
2.2.4. Statistical Analysis. All data were reported as mean ±
standard deviation (SD). Date were analysed by General
Linear Model (Multivariate ANOVA) via SPSS 17.0 (Systat
Software Inc., San Jose, CA, USA). Differences were consid-
ered significant if 𝑃 ≤ 0.05. Pharmacokinetic analyses were
done using WinNonLin (version 4.1; SCI software, Pharsight
Corp., Gary NC, USA).
3. Results
Gliclazide concentrations (𝜇g/g) in the brain tissue are shown
in Table 1.
Table 1 shows that gliclazide concentrations vary in
different parts of the brain and between healthy and diabetic
animals suggesting different extent of penetration. There is
statistically significant difference of gliclazide concentrations
in BS between healthy and diabetic animals without pre-
treatment with DA.Mean gliclazide concentrations are 7-fold
higher in diabetic than those in healthy animals. Also in this
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BS 1.57 ± 0.77 15.49 ± 9.53∗ 11.51 ± 5.48# 33.72 ± 19.58××,×
C 2.22 ± 1.13 23.69 ± 11.45∗ 19.17 ± 8.18# 76.92 ± 34.82××,##
LCH 1.41 ± 0.75 1.87 ± 0.94 0.70 ± 0.38 6.93 ± 4.09××,×
RCH 2.46 ± 1.56 6.33 ± 4.03∗ 2.88 ± 1.30 10.02 ± 6.43××,×
B 1.71 ± 1.03 9.15 ± 5.53∗ 7.27 ± 3.41# 22.00 ± 14.15××,×
LCH: left cerebral hemisphere; RCH: right cerebral hemisphere; BS: brain stem; C: cerebellum, B: total brain.
∗Group 2 versus Group 1, 𝑃 ≤ 0.05; #Group 3 versus Group 1, 𝑃 ≤ 0.05; ×Group 4 versus Group 3, 𝑃 ≤ 0.05; ##Group 4 versus Group 2, 𝑃 ≤ 0.05; ××Group 4
versus Group 1, 𝑃 ≤ 0.05.




















BS 0.09 ± 0.06 1.35 ± 0.92∗ 2.13 ± 1.41# 6.15 ± 4.74××,×
C 0.13 ± 0.06 6.23 ± 3.95∗ 4.40 ± 2.93# 14.05 ± 8.53××
LCH 0.09 ± 0.04 0.11 ± 0.07 0.09 ± 0.04 1.10 ± 0.8××,×
RCH 0.15 ± 0.06 0.46 ± 0.38∗ 0.32 ± 0.23 1.23 ± 0.98××,×
B 0.12 ± 0.06 1.33 ± 1.01∗ 1.66 ± 0.93# 4.09 ± 2.87××,×
LCH: left cerebral hemisphere; RCH: right cerebral hemisphere; BS: brain stem; C: cerebellum, B: total brain.
∗Group 2 versus Group 1, 𝑃 ≤ 0.05; #Group 3 versus Group 1, 𝑃 ≤ 0.05; ×Group 4 versus Group 3, 𝑃 ≤ 0.05; ##Group 4 versus Group 2, 𝑃 ≤ 0.05; ××Group 4
versus Group 1, 𝑃 ≤ 0.05.
part of brain pretreatment with DA leads to the elevation of
concentrations of gliclazide in healthy (10-fold) and diabetic
rats (3-fold) (differences are statistically significant).
Gliclazide concentrations in C are 9-fold higher in dia-
betic than those in healthy animals without DA pretreatment
and are statistically different. Pretreatment with DA resulted
in higher gliclazide concentration in healthy (10-fold) and
diabetic (4-fold) rats, but this differences are not statistically
significant.
In the groups treated with gliclazide only, the concentra-
tions of gliclazide in LCH and RCH are lower than those in
BS and C. It is noticeable that gliclazide concentrations in
RCH are, overall, slightly higher among all treatment group,
than its concentrations in the LCH part of the brain. When
DA was coadministered with gliclazide, the concentrations
of gliclazide in RCH were 3-fold higher in healthy and 4-
fold higher in diabetic animals; differences are statistically
significant. Gliclazide concentrations in LCH were 4-fold
higher in diabetic animals pretreated with DA, while in
healthy animals coadministration of DA had no effect on
gliclazide concentrations comparing to group that received
only gliclazide.
In total brain mass gliclazide concentrations are elevated
in diabetic animals (4-fold, statistically significant) (Table 1).
In groups pretreated with DA gliclazide concentrations are 5-
fold higher in healthy and 3-fold higher in diabetic animals
(differences are statistically significant).
Pretreatment with DA leads to increased variation of
concentrations in all groups and brain parts.












is coefficient of the penetration of gliclazide, 𝐶
𝑏
concentration of gliclazide in brain tissue (𝜇g/g), and𝐶
𝑝
total
gliclazide concentration in serum 240 seconds (𝜇g/mL).
Total drug penetration is 24-fold higher in BS in diabetic
animals than that in healthy animals given gliclazide alone
(Table 2). DA increased penetration of gliclazide in BS 15-fold
in healthy and 3-fold in diabetic animals; both differences are
statistically significant. Effect of diabetes on penetration in C
is more pronounced since drug penetration is 34-fold higher
in diabetic than that in healthy animals. In C DA facilitates
penetration 48-fold in healthy and 3-fold in diabetic animals
(differences are statistically significant). The effect of illness
and bile salt on gliclazide penetration through BBB is lower
in cerebral hemispheres.
Relative brainmass in group of healthy animals pretreated
withDA is 1.2-fold lower than that in group of healthy animals
treated only with gliclazide and is statistically different (rela-
tive brainmass: 0.69±0.05%Group 1 and 0.56±0.03Group 2).
In diabetic animals pretreated with DA relative brain mass is
unchanged in comparison to that of diabetic animals treated
only with gliclazide (relative brainmass: 0.60±0.09%Group 3
and 0.62±0.11%Group4).There are no significant differences
in relative brain masses between other groups.
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(𝜇g/mL): mean ± SD
30 15.13 ± 4.79 22.77 ± 7.50 12.85 ± 5 9.44 ± 5.72
60 23.28 ± 4.75 15.37 ± 5.20 10.65 ± 3.61 8.29 ± 4.92
150 13.94 ± 3.44 10.98 ± 3.75 9.16 ± 4.77 7.22 ± 2.94
240 15.99 ± 4.26 9.79 ± 3.14∗ 11.12 ± 4.56# 7.43 ± 3.92××
∗Group 2 versus Group 1, 𝑃 ≤ 0.05; ××Group 4 versus Group 1, 𝑃 ≤ 0.05; #Group 3 versus Group 1, 𝑃 ≤ 0.05.
Table 4: Areas under the curve of gliclazide serum concentrations (AUC), apparent volume of distribution (Vd), and blood glucose level
(mmol/L) 240 seconds after and before intra-arterial gliclazide injection.
Groups
Mean ± SD
AUC (𝜇g∗ s∗mL−1) Vd (mL) Glucose level (mmol/L)
Before gliclazide After gliclazide (240 s)
Group 1 healthy animals:
gliclazide
𝑛 = 6
4020.43 ± 456.42 219.73 ± 13.47 7.01 ± 0.3 9.55 ± 0.34
∗∗
Group 2 healthy animals:
gliclazide + DA
𝑛 = 6
3931.02 ± 1790.13 1077.19 ± 83.43∗ 8.11 ± 0.60 9.53 ± 0.46∗∗
Group 3 diabetic animals:
gliclazide
𝑛 = 6
2150.16 ± 1472.50 970.15 ± 79.97# 29.04 ± 4.20 30.95 ± 3.86







32.50 ± 5.75 34.3 ± 7.44
Healthy animals / / 7.7 ± 0.3 8.7 ± 0.35
Diabetic animals / / 28.83 ± 2.23 29.33 ± 2.19
Healthy animals with DA
pretreatment / / 6.93 ± 0.6 7.45 ± 1.02
Diabetic animals with DA
pretreatment / / 33.58 ± 4.02 29.7 ± 4.30
∗Group 2 versus Group 1, 𝑃 ≤ 0.05; ××Group 4 versus Group 1, 𝑃 ≤ 0.05; #Group 3 versus Group 1, 𝑃 ≤ 0.05; ∗∗glucose level before versus after gliclazide,
𝑃 ≤ 0.05.
Gliclazide serum concentrations are shown in Table 3.
There are different changes in gliclazide serum concentra-
tions during observed period in examined groups. Gliclazide
serum concentrations 240 seconds are higher in healthy
than those in diabetic animals (statistically significant dif-
ference). Also, DA pretreated groups have lower gliclazide
serum concentration 240 seconds than groups without DA
pretreatment.
Blood glucose levels (mmol/L) and areas under the curve
of gliclazide serum concentrations (AUC) as well as apparent
volume of distribution (Vd) are shown in Table 4. Correlation
between differences of blood glucose levels 240 seconds after
and before application of gliclazide and AUC values is shown
on Figure 1.
Correlation between differences of blood glucose levels
and AUCs is shown in Figure 1 and it is second-order polyno-
mial in all groups. When AUC values of gliclazide are higher
the differences of blood glucose levels 240 seconds after
and before application are smaller. However, after reaching
maximumAUC values the differences of blood glucose levels
are getting higher again.
From Table 4 it can seen that DA alone did not change
the level of glucose neither in healthy nor in diabetic animals.
Treatment with gliclazide in groups of healthy and diabetic
animals with and without pretreatment with DA led to an
increase of blood glucose levels. Such glucose level changes
were not detected in groups of healthy and diabetic animals
treated with only saline solution.
Apparent volumes of distribution in the group of healthy
animals treated with gliclazide alone are lower than those
calculated in other three groups. Healthy animals pretreated
withDAhad 4.8 fold higher Vd than those in group of healthy
animals treated only with gliclazide. Diabetic animals had 1.5
fold lower Vd in group pretreated with bile salt.
4. Discussion
This study showed differences in gliclazide penetration in
various parts of the brain under influence of diabetes mellitus
Journal of Diabetes Research 5
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Figure 1: Scatter plots of Δ blood glucose level (mmol/L) 240 seconds after and before intra-arterial injection of gliclazide versus calculated
AUC values of gliclazide.
and pretreatment with DA.There were higher concentrations
of gliclazide in diabetic animals in comparison to healthy
animals and they are the result of BBB disruption [22].
Also, DA had a direct permeation-enhancing effect on the
antidiabetic drug gliclazide as other bile acids had in previous
studies [23–31]. In group of healthy animals pretreated with
DA distribution of gliclazide in all brain parts was similar
to the one in group of diabetic animals treated only with
gliclazide, which indicates that DA aswell as diabetesmellitus
had direct effect on gliclazide permeability across BBB.
In healthy animals without DA pretreatment concen-
trations of gliclazide were similar in all brain parts, which
implies a one-compartment model of distribution. In other
groups of animals data indicates existence of two compart-
ments where one compartment is cerebellum and brain stem
and the other is hemispheres of the brain. However differ-
ences in gliclazide brain concentrations could be explained in
terms of the distribution of blood vessels and used method of
drug application [32]. Higher concentrations of gliclazide in
brain stem and cerebellum than those in hemispheres could
6 Journal of Diabetes Research
be due to the fact that gliclazide was given in right a. axillaris
which directly through a. vertebralis takes larger amount of
drug to cerebellum and brain stem because they are closer
to the place of application, so these regions get the most of
the given dose [33, 34]. Also, through the right a. carotis
drug is taken to the brain hemispheres where it comes first to
right cerebral hemisphere. Thus concentrations of gliclazide
are higher in right cerebral hemisphere than left cerebral
hemisphere. In group of diabetic animals these differences
in gliclazide concentrations could be additionally explained
with different susceptibility of BBB. It is known that BBB in
brain regions with higher blood vessel density and flow, like it
is in hemispheres, stays longer intact in hyperglycemic state.
Apparent volume of distribution of gliclazide is higher in
diabetic animals than in healthy animals treated only with
gliclazide. Also, apparent volume of distribution of gliclazide
is higher in those animals pretreated with DA than that in
healthy animals treated only with gliclazide. Apparent vol-
umeof distribution is in correlationwith observed concentra-
tions of gliclazide in brain tissuewhere volume of distribution
was higher in groups of diabetic animals and those pretreated
with DA than that in group of healthy animals treated only
with gliclazide. Increased distribution in these groups could
be explained in various ways. It is known that gliclazide is
highly lipophilic small molecule (log𝑃octanol/water = 2.6)
and weak acid with protein binding of 94% [35]. In diabetes
mellitus there is more acidic environment, and thus free
fraction of gliclazide is expected to bemore in its neutral form
which can more easily penetrate BBB [36]. This partly could
explain better penetration of gliclazide in group of diabetic
animals than in healthy animals.However, the problemof this
theory is low solubility of gliclazide which makes it difficult
for gliclazide to diffuse through blood to BBB. It ismore likely
that rapid protein to membrane transfer occurred which was
examined earlier for some hydrophobic drugs [37]. If rat
brain blood flow is 1.25mL/min/g and brain blood volume is
3% of brain weight [38] then transit time of blood through
brain is approximately 1.5 s. In period of 240 seconds 160
transit times occur thus gliclazide could penetrate through
BBB by rapid protein to membrane transfer.
Diabetic animals have better penetration of gliclazide
through BBB than healthy animals. Groups of healthy and
diabetic animals pretreated with DA have lower AUCs and
higher CNS concentrations.
There is second-order polynomial correlation of AUCs
with differences of blood glucose levels in all groups, where
when AUCs are higher the differences of blood glucose levels
are smaller till a breaking point when continued increase
of AUCs leads to higher blood glucose level differences.
This data suggests that too high gliclazide serum levels
(AUCs) lead to inefficient blood glucose level control. Also
DA changed pattern of the blood glucose level increase and
changed polynomial function.
It is shown that DA enhances permeability through BBB
in diabetic and healthy animals. Cell lysis is one of the
possible mechanism of the BBB opening, which is unlikely
to be the case in this investigation since concentration of
bile salt at the site was lower than 1.5mM [17, 36]. Probable
mechanism of BBB opening is modification of tight junction
or incorporation of bile salt in membrane bilayer. Also,
previously it was found that the infusion of bile salts led to
opening of the BBB and edemas of the rat brain [39]. In this
study brain edemas were not observed since relative brain
mass was not higher in groups of animals pretreatedwithDA.
5. Conclusions
Deoxycholic acid promotes gliclazide penetration across BBB
in diabetic and in healthy animals. In addition, deoxycholic
acid alters some pharmacokinetic properties of gliclazide in
both healthy anddiabetic rats. Deoxycholic acid pretreatment
also changed the pattern of blood glucose level increase after
gliclazide application in diabetic as well as in healthy animals.
Thus deoxycholic acid should be more investigated in the
treatment of diabetes mellitus and as permeation promoter of
lipophilic molecules through BBB as well as other biological
membranes.
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AUC: Areas under the curve of gliclazide
serum concentrations (𝜇g ∗ s ∗mL−1)
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: Total gliclazide concentration in serum
in 240th second (𝜇g/mL)
DA: Sodium salt of deoxycholic acid
DCH: Right cerebral hemisphere
LCH: Left cerebral hemisphere
TJ: Tight junction
Vd: Apparent volume of distribution (mL).
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